Cancer Chemotherapy and Pharmacology

, Volume 31, Issue 2, pp 123–126 | Cite as

The importance of schedule on diethyldithiocarbamate modulation of drug-induced myelosuppression

  • Christopher J. East
  • Richard F. Borch
Original Articles Myelosuppression, Diethyldithiocarbamate


Sodium diethyldithiocarbamate (DDTC) has been investigated as a biochemical modulator of the toxicity associated with clinically used cancer chemotherapeutic agents. In the present study, we assessed the ability of DDTC to accelerate recovery of the granulocyte/macrophage progenitor cel (GM-CFC) population following treatment with the myelosuppressive drugs carboplatin (CBDCA), tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum(IV) (tetraplatin), 5-fluorouracil (5-FU), and etoposide (VP-16) in B6D2F1 mice. Myelotoxicity was assessed 24 h after the injection of the anticancer drug using a GM-CFC clonogenic assay. In the case of all four anticancer drugs, the timing of DDTC administration appeared to be a critical parameter with regard to protection. A delay time of 1 h between the injection of the myelotoxic drug and treatment with DDTC (30 mg/kg) resulted in a significant reduction in cytotoxicity to GM-CFC, whereas a longer delay time did not. These results suggest that the timing of DDTC administration may be essential in modulating the myelosuppression associated with many chemotherapeutic regimens used in the clinic.


Delay Time Etoposide Carboplatin Chemotherapeutic Agent Anticancer Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



sodium diethyldithiocarbamate






tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum(IV)


granulocyte/macrophage colony-froming unit


α-minimum essential medium


pokeweed mitogen-stimulated spleen-cell conditioned medium


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Berry JM, Jacobs C, Sikic B, Halsey J, Borch RF (1990) Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol 8: 1585Google Scholar
  2. 2.
    Carfagna PF, Chaney SG, Chang J, Holbrook DJ (1990) Reduction of tetrachloro(d,l-trans)1,2-diaminocylohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC),S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat. Fundam Appl Toxicol 14: 706Google Scholar
  3. 3.
    Carter SK, Bakowski MT, Hellman K (1981) Chemotherapy of cancer. Wiley, New York, p 59Google Scholar
  4. 4.
    Dorr RT, Fritz WL (1980) Cancer chemotherapy handbook. Elsevier/North Holland, New York, p 101Google Scholar
  5. 5.
    Evans RG, Wheatley C, Engel C, Nielsen J, Ciborowski LJ (1984) Modification of the bone marrow toxicity ofcis-diamminedichloroplatinum(II) in mice by diethyldithiocarbamate. Cancer Res 44: 3686Google Scholar
  6. 6.
    Gandara DR, DeGregorio M, Perez EA, Holleran W, Denham A, Lawrence HJ, Borch RF (1988) Diethyldithiocarbamate (DDTC) rescue following very high-dose cisplatin (200 mg/m2/cycle) in nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 7: 107Google Scholar
  7. 7.
    Gringeri A, Keng PC, Borch RF (1988) Diethyldithiocarbamate inhibition of bone marrow toxicity caused by cisplatin or carboplatin. Cancer Res 48: 5708Google Scholar
  8. 8.
    Masuda N, Fukuoka M, Matsui K, Negoro S, Takada M, Sakai N, Ryu S, Takifuji N, Ito K, Kudoh S, Kusunoki Y (1990) Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer. Cancer 65: 2635Google Scholar
  9. 9.
    Pannaccuilli IM, Lerza RA, Bogliolo GV, Mencoboni MP, Saviane AG (1989) Effect of diethyldithiocarbamate on toxicity of doxorubicin, cyclophosphamide, andcis-diamminedichloroplatinum(II) on mice haematopoietic progenitor cells. Br J Cancer 59: 371Google Scholar
  10. 10.
    Rothenberg ML, Ostchega Y, Steinberg SM, Young RC, Hummel S, Ozols RF (1988) High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer. J Natl Cancer Inst 80: 1488Google Scholar
  11. 11.
    Schmalbach TK, Borch RF (1989) Myeloprotective effect of diethyldithiocarbamate treatment following 1,3-bis-(chloroethyl)-1-nitrosourea, Adriamycin, or mitomycin C in mice. Cancer Res 49: 2574Google Scholar
  12. 12.
    Schmalbach TK, Borch RF (1989) Diethyldithiocarbamate modulation of murine bone marrow toxicity induced bycis-diammine(cyclobutanedicarboxylato)platinum(II). Cancer Res 49: 6629Google Scholar
  13. 13.
    Schmalbach TK, Borch RF (1990) Mechanism of diethyldithiocarbamate modulation of murine bone marrow toxicity. Cancer Res 50: 6218Google Scholar
  14. 14.
    Siegers MP, Feinendegen LE, Lahiri SK, Cronkite EP (1979) Relative number and proliferation kinetics of hemopoietic stem cells in the mouse. Blood Cells 5: 211Google Scholar
  15. 15.
    Trump DL, Hortvet L (1985) Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms. Cancer Treat Rep 69: 259Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Christopher J. East
    • 1
  • Richard F. Borch
    • 1
  1. 1.Department of Pharmacology and Cancer CenterUniversity of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations